MA29273B1 - Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur - Google Patents
Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseurInfo
- Publication number
- MA29273B1 MA29273B1 MA30171A MA30171A MA29273B1 MA 29273 B1 MA29273 B1 MA 29273B1 MA 30171 A MA30171 A MA 30171A MA 30171 A MA30171 A MA 30171A MA 29273 B1 MA29273 B1 MA 29273B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunosuppresseur
- xolair
- omalizumab
- agent
- synergistic combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTICORPS ANTI-IGE, ET AU MOINS UN AGENT IMMUNOSUPPRESSEUR ADDITIONNEL, DANS LAQUELLE LES INGRÉDIENTS ACTIFS SONT PRÉSENTÉS DANS CHAQUE CAS SOUS FORME LIBRE OU SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, ET ÉVENTUELLEMENT AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, ET SONT DESTINÉS À ÊTRE ADMINISTRÉ SIMULTANÉMENT, SÉPARÉMENT, OU SUCCESSIVEMENT.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0502358.5A GB0502358D0 (en) | 2005-02-04 | 2005-02-04 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29273B1 true MA29273B1 (fr) | 2008-02-01 |
Family
ID=34355808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30171A MA29273B1 (fr) | 2005-02-04 | 2007-08-28 | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080206237A1 (fr) |
EP (1) | EP1846031A1 (fr) |
JP (1) | JP2008528650A (fr) |
KR (1) | KR20070100344A (fr) |
CN (1) | CN101111265A (fr) |
AR (1) | AR053541A1 (fr) |
AU (1) | AU2006210098A1 (fr) |
BR (1) | BRPI0607349A2 (fr) |
CA (1) | CA2595976A1 (fr) |
GB (1) | GB0502358D0 (fr) |
GT (1) | GT200600023A (fr) |
IL (1) | IL184713A0 (fr) |
MA (1) | MA29273B1 (fr) |
MX (1) | MX2007009436A (fr) |
NO (1) | NO20074497L (fr) |
PE (1) | PE20061203A1 (fr) |
RU (1) | RU2007132980A (fr) |
TN (1) | TNSN07304A1 (fr) |
TW (1) | TW200640487A (fr) |
WO (1) | WO2006082052A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1850865A2 (fr) * | 2005-02-08 | 2007-11-07 | Novartis AG | Induction d'un anticorps antilymphocyte |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
ES2708842T3 (es) * | 2008-09-17 | 2019-04-11 | Xencor Inc | Composiciones y métodos para para tratar trastornos mediados por IgE |
KR20120102125A (ko) * | 2009-12-18 | 2012-09-17 | 사노피 | Gpvi에 대한 신규한 길항제 항체 및 그의 fab 단편 및 그의 용도 |
JP6030452B2 (ja) | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
CN103492565B (zh) | 2011-02-25 | 2021-01-29 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
AR085749A1 (es) * | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
EP3939996A1 (fr) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques |
TW201809008A (zh) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
KR20180095740A (ko) | 2015-02-27 | 2018-08-27 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
US10947320B2 (en) | 2015-12-18 | 2021-03-16 | University Of Notre Dame Du Lac | Covalent heterobivalent antibody inhibitors and ligands |
WO2017110981A1 (fr) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-myostatine et procédés d'utilisation |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CA3026050A1 (fr) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition pour la prophylaxie ou le traitement de maladies liees a il-8 |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
US12030959B1 (en) | 2023-07-05 | 2024-07-09 | Genentech, Inc. | Anti-IgE antibody therapy for multiple food allergies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-04 GB GBGB0502358.5A patent/GB0502358D0/en not_active Ceased
-
2006
- 2006-01-18 GT GT200600023A patent/GT200600023A/es unknown
- 2006-02-02 PE PE2006000134A patent/PE20061203A1/es not_active Application Discontinuation
- 2006-02-02 CA CA002595976A patent/CA2595976A1/fr not_active Abandoned
- 2006-02-02 KR KR1020077017947A patent/KR20070100344A/ko not_active Application Discontinuation
- 2006-02-02 US US11/814,871 patent/US20080206237A1/en not_active Abandoned
- 2006-02-02 JP JP2007553536A patent/JP2008528650A/ja active Pending
- 2006-02-02 CN CNA2006800039151A patent/CN101111265A/zh active Pending
- 2006-02-02 EP EP06706581A patent/EP1846031A1/fr not_active Withdrawn
- 2006-02-02 AU AU2006210098A patent/AU2006210098A1/en not_active Abandoned
- 2006-02-02 AR ARP060100378A patent/AR053541A1/es not_active Application Discontinuation
- 2006-02-02 RU RU2007132980/13A patent/RU2007132980A/ru not_active Application Discontinuation
- 2006-02-02 WO PCT/EP2006/000911 patent/WO2006082052A1/fr active Application Filing
- 2006-02-02 BR BRPI0607349-2A patent/BRPI0607349A2/pt not_active Application Discontinuation
- 2006-02-02 MX MX2007009436A patent/MX2007009436A/es not_active Application Discontinuation
- 2006-02-03 TW TW095103825A patent/TW200640487A/zh unknown
-
2007
- 2007-07-19 IL IL184713A patent/IL184713A0/en unknown
- 2007-08-03 TN TNP2007000304A patent/TNSN07304A1/en unknown
- 2007-08-28 MA MA30171A patent/MA29273B1/fr unknown
- 2007-09-04 NO NO20074497A patent/NO20074497L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101111265A (zh) | 2008-01-23 |
TW200640487A (en) | 2006-12-01 |
AU2006210098A1 (en) | 2006-08-10 |
KR20070100344A (ko) | 2007-10-10 |
GB0502358D0 (en) | 2005-03-16 |
JP2008528650A (ja) | 2008-07-31 |
TNSN07304A1 (en) | 2008-12-31 |
NO20074497L (no) | 2007-10-26 |
PE20061203A1 (es) | 2006-12-19 |
AR053541A1 (es) | 2007-05-09 |
IL184713A0 (en) | 2007-12-03 |
CA2595976A1 (fr) | 2006-08-10 |
RU2007132980A (ru) | 2009-03-10 |
BRPI0607349A2 (pt) | 2009-09-01 |
GT200600023A (es) | 2006-08-16 |
MX2007009436A (es) | 2007-08-17 |
EP1846031A1 (fr) | 2007-10-24 |
WO2006082052A1 (fr) | 2006-08-10 |
US20080206237A1 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
NO2014016I2 (no) | Dimetylfumarat | |
HK1080364A1 (en) | Oral pharmaceutical forms of liquid drugs having improved bioavailability | |
CY1114594T1 (el) | Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη | |
WO2002042462A3 (fr) | Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique | |
BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
MXPA04000920A (es) | Derivados de aminoisoxazol activos como inhibidores de la cinasa. | |
EA200401009A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
WO2005094374A3 (fr) | Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci | |
WO2002028999A3 (fr) | Profils d'expression genique dans les cellules granulocytaires | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
MA29675B1 (fr) | Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione | |
BRPI0414721A (pt) | formulações estabilizadas de fosfatidilserina | |
DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
BRPI0410049A (pt) | composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico | |
EE200100104A (et) | 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm | |
MXPA03010054A (es) | Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. | |
WO2005044186A3 (fr) | Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques | |
SE9902935D0 (sv) | Pharmaceutical compositions | |
EA200702386A1 (ru) | Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения | |
BR0011845A (pt) | Complexo farmacêutico | |
BR0313175A (pt) | Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina |